Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 5Neoplasm Metastasis 5Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma 2Vaccinia 1Uterine Cervical Neoplasms 1Squamous Non-small Cell Lung Cancer 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Ductal Adenocarcinoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Melanoma 1Locally Advanced Pancreatic Cancer 1Gastric Adenocarcinoma 1Gallbladder Cancer Unresectable 1Diabetes Mellitus, Insulin-Dependent, 12 1Colonic Neoplasms 1Carcinoma, Pancreatic Ductal 1Brain Neoplasms 1Anal Cancer Metastatic 1

Interventions

pembrolizumab 2tremelimumab 1poly ICLC 1lenvatinib 1durvalumab 1balstilimab 1Peptides 1Pemetrexed 1Carboplatin 1Blood Specimen Collection 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × 130-nm albumin-bound paclitaxel × 30 days × Clear all
NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Active not recruiting
400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡